AFFILIATIONS
1 CHU Lille, Lille, France
2 Hopital Foch, APHP, PARIS, France
3 CHU LILLE, Lille, France
4 Hôpital Saint Antoine, APHP, Sorbonne Université, Paris, Paris, France
5 CHU LILLE, LILLE, France
6 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
7 CH Intercommunal de Creteil, Creteil, France
8 CHU Nantes, Nantes, France
9 Centre Hospitalier Annecy-Genevois, Annecy, France
10 CHU Limoges, Limoges, France
11 Hôpital Cochin, AP-HP, Paris, France, Paris, France
12 CHU Tours, Tours, France
13 CH Avignon, Avignon, France
14 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
15 Hopital Bichat, Paris, France
16 Saint-Louis Hospital, AP-HP, Paris, France
17 Hopital UNEOS, Ventoux, France
18 CHU Nantes, Nantes, France
19 CHU de Toulouse, Toulouse, France
20 GH70 (Site principal de Vesoul), Vesoul, France
21 CHU Amiens, Amiens, France
22 CH NIORT, NIORT, France
23 CH SAINT NAZAIRE, CH SAINT NAZAIRE, France
24 HCL, Lyon, France
25 CHU La Pitié-Salpétrière - AP/HP, Paris, France
26 CHU LIMOGES, Limoges, France
27 CHU Angers, Angers, France
28 CH Dax, Dax, France
29 CHU BORDEAUX, BORDEAUX, France
30 CHU NICE, NICE, France
31 CHU BESANCON, BESANCON, France
32 Groupe Hospitalier de la Région Mulhouse et Sud Alsace, Mulhouse, France
33 catherine.mohr@chu-reunion.fr, Saint Pierre - La REUNION, Reunion
34 Centre Hospitalier Annecy Genevois (CHANGE), Annecy, France
35 CHU CAEN, CAEN, France
36 t.moulinet@chu-nancy.fr, Nancy, France
37 CHU Toulouse, Toulouse, France
38 Hôpital Edouard Herriot - Lyon, Lyon, France
39 CHU Nantes, Nantes, France
40 CH valence, Valence, France
41 CHU Reims, Reims, France
42 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
43 Hospices Civils de Lyon, Lyon, France
44 Hopital Saint Louis - APHP, Saint-Louis, France
45 CH VIHCY, VICHY, France
46 CHU Lille, Lille, France
47 CHU Lille, Lille, France
48 CHU STRASBOURG ICANS, Strasbourg, France
49 CH La Roche sur Yon, La Roche sur Yon, France
50 Hopital Ambroise-Paré, Boulogne-Billancourt, France
51 CHU Lille, Reference Center for Hypereosinophilic Syndromes (CEREO), Lille, France
ABSTRACT
Introduction.
The CD3-CD4+ lymphocytic-variant hypereosinophilic syndrome (HES-L) is a rare, indolent clonal T-cell disorder. Clinical manifestations arise from two mechanisms: eosinophil-driven organ damage and symptoms caused directly by the T-cell clone, independent of eosinophilia. This dual pathophysiology complicates treatment, as therapies targeting eosinophils may not adequately control T-cell-mediated manifestations. HES-L is characterized by a highly corticosteroid-dependent course, yet evidence supporting steroid-sparing therapies remains limited, and no treatment algorithm has been established.
Methods.
LYMPHEo is a retrospective multicenter cohort including patients with CD3-CD4+ HES-L diagnosed between 2002 and 2025. The objective was to evaluate the clinical and hematological responses to the treatments used. Complete clinical response (CCR) was defined as resolution of disease manifestations with prednisone-equivalent doses ≤5 mg/day; partial clinical response (PCR) as clinical improvement allowing glucocorticoid tapering without meeting CCR criteria; and no clinical response (NCR) if neither criterion was met. Complete hematologic response (CHR) was defined as an absolute eosinophil count (AEC) <0.5 × 10?/L; partial hematologic response (PHR) as a ≥50% reduction in AEC without achieving CHR; and no hematologic response (NHR) if neither criterion was met. The study received approval from the local ethics committee (IRB00012437).
Results.
Ninety-five patients were included (median age at diagnosis: 45.0 years [IQR: 35.0-59.0]). The median follow-up was 61.0 months (27.0; 97.0). Skin involvement occurred in 89% of patients, followed by lymphadenopathy and/or splenomegaly (37%) and musculoskeletal manifestations (23%). The median CD3-CD4+ T-cell proportion was 6.8% (2.0; 18.6). Glucocorticoids were used in 80%, primarily for long-term treatment. The median initial dose was 40.0 mg/day (20.0; 60.0), and the median threshold for glucocorticoid dependence was 10 mg/day (10.0; 20.0).
Among 34 patients receiving interferon-α (including 29 as first-line therapy), the overall clinical response was 62% (CCR 41%; PCR 21%), with CHR in 50%. The median glucocorticoid dose decreased from 15 mg/day (10.0; 20.0) to 8.8 mg/day (0.0; 11.3) (p=0.0002), allowing complete withdrawal in 27%. Among the 33 patients treated with mepolizumab (including 18 as first-line therapy), hematologic responses markedly exceeded clinical responses (CHR 61% vs CCR 24%), highlighting a marked discrepancy between hematologic control and clinical improvement. The median glucocorticoid dose decreased from 10 to 5.5 mg/day, allowing complete withdrawal in 34%. Notably, seven of eight patients with persistent clinical disease despite interferon-α remained clinical non-responders after switching to mepolizumab.
Despite its use in later-line therapy, ruxolitinib achieved clinical responses in 91% of patients (CCR 73%, PCR 18%), together with CHR in 60% and substantial glucocorticoid sparing (median dose: 5 to 0 mg/day). Mogamulizumab (anti-CCR4) induced clinical responses in all six treated patients (CCR 3/6, PCR 3/6) and was associated with a reduction in the size of the circulating abnormal T-cell clone in 2/6 patients and normalization (<0.5% of all lymphocytes) in 4/6. It also achieved CHR in 4/6 patients and reduced the median glucocorticoid dose from 22.5 mg/day (12.5; 25.0) to 5 mg/day (5.0; 8.8). Three of five evaluable patients relapsed a median of 20 months (IQR: 16.0; 22.0) after treatment discontinuation. Among patients presenting with episodic angioedema with eosinophilia (n=21), mepolizumab was ineffective in 8/10 patients. Interferon-α achieved CCR in 4/9 patients, and all five patients treated with ruxolitinib responded (CCR 4/5; PCR 1/5).
Conclusion.
As the largest reported cohort of CD3-CD4+ HES-L, this study provides a comprehensive overview of current treatment outcomes. Although both interferon-α and mepolizumab enabled glucocorticoid tapering, mepolizumab was associated with a marked discrepancy between hematological control and clinical improvement. Ruxolitinib and mogamulizumab showed particularly promising efficacy in refractory disease and warrant prospective evaluation.